NEWS

Coulter Partners recruits Chief Financial Officer for BONESUPPORT

Coulter Partners was delighted to partner with BONESUPPORT AB to secure the appointment of Björn Westberg as Chief Financial Officer and Director. A Scandinavian medical technology company, BONESUPPORT AB is an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery.

Mr Westberg brings nearly 30 years’ finance and management experience to BONESUPPORT. He joins from Recipharm AB – one of the largest pharmaceutical contract manufacturers in the world – where he has been CFO since 2007. Prior to this he was CFO of the Nasdaq listed software company Jeeves (2001-2007), and before that held senior roles at AstraZeneca, among these Finance Director ISMO Northern Europe and Controller in Astra Japan.

“I am very pleased to welcome Björn to the BONESUPPORT team. He brings with him a wealth of finance and management experience that will be crucial to the future growth and development of the company and I thank the outstanding team at Coulter Partners for their collaboration on this search. With the recent appointments of Dr. Hakan Björklund as Chairman and Tone Kvåle as a Non-executive Director to strengthen the Board, and Patrick O’Donnell joining to drive our rapidly growing North American business, we are building a first rate team with the experience and talent that will help us realise the significant potential of our CERAMENT™ platform,” comments Richard Davies, CEO of BONESUPPORT.

Bianca Coulter, CEO of Coulter Partners, adds: “We have known Richard for many years throughout his exciting career at Amgen and Hospira prior to taking the leadership reins at BONESUPPORT. We are extremely proud to be helping Richard and the Board of BONESUPPORT to build this ground-breaking company globally.”

Mr Westberg says: “I look forward to joining BONESUPPORT, where I am confident that my experience will be important as we grow the sales of CERAMENT BVF, CERAMENT G and CERAMENT V and invest in clinical data that will further differentiate these products in the minds of surgeons and payers. BONESUPPORT also has an exciting product pipeline, based on the unique drug eluting properties of its proprietary CERAMENT platform which will be targeting the treatment of a broader range of bone diseases.”